Related Experiment Video
Updated: Aug 11, 2026

Strategic Endothelial Cell Tube Formation Assay: Comparing Extracellular Matrix and Growth Factor Reduced Extracellular Matrix
Published on: August 14, 2016
c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1
B Jiménez1, O V Volpert, F Reiher
1Departamento de Bioquímica, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.
Insights
Thrombospondin-1 (TSP-1), an angiogenesis inhibitor, activates c-Jun N-terminal kinases (JNK) via the CD36 receptor. This JNK activation is crucial for TSP-1 to block new blood vessel formation.
Area of Science:
- Molecular biology
- Cell biology
- Biochemistry
Background:
- Thrombospondin-1 (TSP-1) inhibits angiogenesis by acting on endothelial cells through the CD36 receptor.
- TSP-1 blocks endothelial cell migration, proliferation, and morphogenesis, and inhibits neovascularization in vivo.
Purpose of the Study:
- To investigate the molecular mechanisms by which TSP-1 inhibits angiogenesis.
- To determine the role of mitogen-activated protein kinases (MAPK) and c-Jun N-terminal kinases (JNK) in TSP-1-mediated anti-angiogenic signaling.
Main Methods:
- Studied the effect of TSP-1 on MAPK and JNK activation in endothelial cells.
- Utilized CD36 blocking antibodies and TSP-1-derived peptides to assess the role of CD36.
- Examined corneal neovascularization in JNK-1 deficient mice.
Main Results:
- TSP-1 did not affect MAPK activation by angiogenesis inducers.
- TSP-1 rapidly and transiently activated JNK, dependent on CD36 engagement.
- Inhibition of corneal neovascularization by TSP-1 was significantly reduced in JNK-1 null mice.
Conclusions:
- TSP-1 inhibits angiogenesis through the activation of JNK, a stress-activated kinase.
- CD36 is essential for TSP-1-induced JNK activation and subsequent anti-angiogenic effects.
- JNK plays a critical role in TSP-1's ability to block neovascularization.
Abstract:
Thrombospondin-1 (TSP-1) is a potent inhibitor of angiogenesis that acts directly on endothelial cells via the CD36 surface receptor molecule to halt their migration, proliferation, and morphogenesis in vitro and to block neovascularization in vivo. Here we show that inhibitory signals elicited by TSP-1 did not alter the ability of inducers of angiogenesis to activate p42 and p44 mitogen-activated protein kinase (MAPK). Rather, TSP-1 induced a rapid and transient activation of c-Jun N-terminal kinases (JNK). JNK activation by TSP-1 required engagement of CD36, as it was blocked by antagonistic CD36 antibodies and stimulated by short anti-angiogenic peptides derived from TSP-1 that act exclusively via CD36. TSP-1 inhibition of corneal neovascularization induced by bFGF was severely impaired in mice null for JNK-1, pointing to a critical role for this stress-activated kinase in the inhibition of neovascularization by TSP-1.
More Related Videos
Related Concept Videos
Mechanism of Angiogenesis
Regulation of Angiogenesis and Blood Supply
MAPK Signaling Cascades
The JAK-STAT Signaling Pathway
TGF - β Signaling Pathway
Intracellular Signaling Affects Focal Adhesions
Some...

